Objective: The primary aim of the study was to assess whether both the amount and pace of daily walking were associated with circulating antioxidant capacity in symptomatic patients with peripheral artery disease (PAD).
Peripheral artery disease (PAD) is a highly prevalent, costly, and deadly condition, particularly in those older than 60 years. [1] [2] [3] Furthermore, PAD leads to limitations in patient-perceived health-related quality of life, primarily because of walking dysfunction and leg pain. 4 Consequently, patients with PAD have low daily activity levels, impaired physical function, and faster rates of functional decline and mobility loss over time compared with those without PAD. 5, 6 A possible mechanism for poor walking in older patients with PAD is their chronically high levels of inflammation and oxidative stress, which lead to muscle breakdown and sarcopenia. [7] [8] [9] Patients with PAD have higher levels of inflammation than controls do, and inflammation and antioxidant capacity are predictors of exercise performance and microcirculation of the ischemic calf musculature during exercise. 7, 10, 11 We have reported that circulating inflammatory biomarkers are associated with community-based daily walking in symptomatic patients with PAD, but it is not known whether physical activity modifies circulating antioxidant capacity. 12 It is established that physical activity reduces oxidative stress and increases the ability to respond to oxidative challenges in older adults, suggesting that antioxidant capacity may be increased in older adults who are physically active. [13] [14] [15] [16] However, the influence of monitored daily walking on antioxidant capacity in symptomatic patients with PAD, who typically have greater cardiovascular burden and inflammation than healthy older adults do, has not been addressed. 12, [17] [18] [19] The primary aim of the study was to assess whether both the amount and pace of daily walking were associated with circulating antioxidant capacity in symptomatic patients with PAD. A secondary aim was to determine whether the daily walking measures were associated with circulating inflammation and with endothelial cell inflammation, oxidative stress, and apoptosis. Our primary hypothesis was that more daily strides and faster cadence would be associated with increased levels of circulating antioxidant capacity.
METHODS

Patients
Approval and informed consent. The Institutional Review Board at the University of Oklahoma Health Sciences Center approved the procedures of this study. Written informed consent was obtained from each patient at the beginning of investigation.
Recruitment. Patients who were not currently exercising were recruited from vascular laboratories and vascular clinics from the University of Oklahoma Health Sciences Center for possible enrollment into an exercise rehabilitation program to treat leg pain secondary to PAD.
Baseline clinical characteristics obtained from a medical history and physical examination. Patients were evaluated in the morning at the Clinical Research Center at the University of Oklahoma Health Sciences Center. Patients arrived fasted but were permitted to take their usual medications. To begin the study visit, patients were evaluated with a medical history and physical examination in which demographic information, height, weight, waist circumference, cardiovascular risk factors, comorbid conditions, claudication history, ankle-brachial index (ABI), and a list of current medications were obtained. Following the medical history and physical examination, nursing personnel obtained blood samples, and exercise personnel performed the exercise tests. The nursing and exercise personnel were blinded to the results from the medical history and physical examination.
Inclusion and exclusion criteria. Patients who were limited by symptomatic PAD were included in this study if they met the following criteria: history of ambulatory leg pain, ambulatory leg pain confirmed by treadmill exercise, and ABI #0.90 at rest or #0.73 after exercise. 4, 20, 21 Patients were excluded for the following conditions: absence of PAD (ABI >0.90 at rest and ABI >0.73 after exercise), noncompressible vessels (ABI $1.40), asymptomatic PAD, use of medications indicated for the treatment of claudication (cilostazol or pentoxifylline) initiated within 3 months before investigation, exercise limited by other diseases or conditions, active cancer, end-stage renal disease (defined as stage 5 chronic kidney disease), and abnormal liver function.
Measurements
Claudication onset time (COT) and peak walking time (PWT) obtained from a graded maximal treadmill test. Patients completed a graded treadmill test to determine study eligibility and then repeated the test on a following visit within 1 week to obtain the outcome measures of COT and PWT. 4, 22 Using our procedures, the test-retest intraclass reliability coefficient is R ¼ .89 for COT and R ¼ .93 for PWT. 4 Total walk distance obtained from a 6-minute walk test. Patients performed an over-ground 6-minute walk test supervised by trained exercise technicians. 23 The total distance walked during the test was recorded. The test-retest intraclass reliability coefficient is R ¼ .94 for total 6-minute walking distance.
23
Daily walking obtained from a step activity monitor. Daily walking was measured using a step activity monitor (StepWatch3; Ortho Innovations, Oklahoma City, Okla). 24 Walking was measured during a consecutive 7 days in which patients were instructed to wear the monitor during waking hours and to remove it before retiring to bed and while showering. The step activity monitor was attached to the right ankle above the lateral malleolus by an elastic Velcro strap and continuously recorded the number of strides taken each day and the number of minutes spent walking each day. The daily number of strides and walking time are further analyzed by the software program to determine the peak activity index, obtained by ranking all minutes of the day according to cadence, then taking the average of the highest 30 values. The outcome measures are recorded for each day, and then the daily averages are averaged over the 7-day monitoring period. The accuracy of the step activity monitor exceeds 99% 6 1% in patients with claudication, and the test-retest intraclass reliability coefficient for the daily ambulatory activity measures ranges from R ¼ .83 to R ¼ .94. 24 Blood sampling. Approximately 10 mL of blood was drawn by venipuncture from an antecubital vein once at baseline, collected in Vacutainers (Becton Dickinson, Franklin Lakes, NJ), and distributed in 0.5-mL aliquots. The samples were stored at À80 C and subsequently batched for analysis. Serum antioxidant capacity. Hydroxyl radical antioxidant capacity (HORAC) was measured from sera using the OxiSelect (Cell Biolabs Inc, San Diego, Calif) HORAC activity assay to determine the capacity of antioxidant The authors suggest that homebased walking programs may increase endogenous antioxidant capacity; still to be proven is the association between increased oxidative stress and poor walking capacity.
enzymes and other redox molecules to counterbalance the deleterious effects of oxidative stress in the sera of patients. 8 High-sensitivity C-reactive protein (hs-CRP). The concentration of hs-CRP was quantified from 300 mL of sera using a high-sensitivity near-infrared particles immunoassay. The Synchron LX20 (Beckman-Coulter, Brea, Calif), a commercially available device, was used to perform the assay. Before each assay was performed, the Synchron system was calibrated, and a calibration curve was established. 25 Endothelial cell cultures. A cell culture-based bioassay approach using cultured primary human arterial endothelial cells was used to characterize the endothelial effects of circulating factors present in the sera of patients. In brief, endothelial cells (purchased from Cell Applications, Inc, San Diego, Calif, after passage 4; age of the donors is unknown) were initially cultured in MesoEndo Cell Growth Medium (Cell Applications, Inc) followed by Endothelial Cell Basal Medium supplemented with 10% fetal calf serum until the time of serum treatment, as described. 8 Interindividual variance is unlikely to contribute to observed differences because detector cells used for each in vitro study were from the same donor. For treatment, fetal calf serum was replaced with serum (10%; for 24-48 hours) collected from our patients. 8 Cells cultured in Endothelial Cell Basal
Medium supplemented with 10% fetal calf serum served as an additional control. Apoptosis assay. Cultured endothelial cells were treated with sera from patients for 24 hours. Caspase activities using Caspase-Glo 3/7 assay kit (Promega, Madison, Wisc) were measured to assess apoptotic cell death, as previously reported. 8 Cellular reactive oxygen species production. Hydrogen peroxide production in detector endothelial cells was measured fluorometrically using the Amplex red/horseradish peroxidase assay to determine cellular oxidative stress induced by factors present in the sera. 8 Transient transfection, nuclear factor kB reporter gene assay. Transcriptional activity of nuclear factor kB was tested in serum-treated detector endothelial cells by a reporter gene assay to determine cellular proinflammatory effects induced by factors in the sera. 8 Transfections in endothelial cells were performed using the Amaxa Nucleofector technology (Amaxa, Gaithersburg, Md), as we have previously reported. 8 
Statistical analyses
To summarize the clinical characteristics, daily ambulatory activity, and vascular biomarkers, continuous variables were presented as means and standard deviations, and binary variables were presented as percentages.
Each of the total stride and the walking pace variables were evenly trichotomized into a discrete variable with three groups according to tertiles, and the two discrete variables were used in subsequent statistical analyses. Continuous outcome variables included HORAC, hs-CRP, and three endothelial cell biomarkers. All five outcome variables were compared among three total stride groups and three walking pace groups using the one-way analysis of variance model. In addition, adjusted analyses were performed after adjusting for age, sex, race, and ABI.
All statistical analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC). P values <.05 were considered to be statistically significant.
RESULTS
The clinical characteristics, daily ambulatory activity, and vascular biomarkers of 244 patients with claudication are shown in Table I . The group consisted of a nearly NF-kB, nuclear factor kB; PWT, peak walking time.
Values are means (standard deviation) or percentages.
even distribution of men and women and whites and African Americans. On average, the group was on the borderline between being overweight and obese, had typical ABI values for patients with claudication, had typical ambulatory limitations during a treadmill test and 6-minute walk test, and had a high prevalence of cardiovascular risk factors (particularly hypertension, dyslipidemia, and metabolic syndrome). On average, the patients were relatively sedentary as they accumulated 3300 strides/d (6600 steps), and their mean peak ambulatory cadence was slow as it was <30 strides/min. Furthermore, the group had relatively low mean antioxidant capacity and high hs-CRP and endothelial cell biomarker values. The vascular biomarkers of patients grouped into tertiles by the amount of daily walking are displayed in Table II . Patients in the low tertile took the fewest strides per day (#2400), individuals in the middle tertile took between 2401 and 3835 strides/d, and patients in the high tertile took >3835 strides/d. HORAC was higher in the middle (P ¼ .03) and high (P ¼ .01) stride tertiles than in the low tertile, but there was no difference between middle and high tertiles (P ¼ .44). After adjusting for age, sex, race, and ABI, similar findings were obtained for group differences in HORAC. The concentration of hs-CRP was significantly lower in middle (P < .01) and high (P < .01) stride tertiles than in the low tertile, but there was no difference in hs-CRP values between middle and high tertiles (P ¼ .25). For the adjusted analyses, similar findings were obtained for group differences in hs-CRP. No significant group differences were noted for the endothelial cell biomarkers in either the unadjusted or adjusted analyses.
The vascular biomarkers of patients grouped into tertiles by the pace of daily walking are displayed in Table III . Patients in the low tertile had the slowest peak cadence (#25.0 strides/min), individuals in the middle tertile walked at a peak cadence between 25.1 and 31.6 strides/min, and patients in the high tertile walked at the fastest peak cadence of >31.6 strides/min. HORAC was higher in the high cadence tertile than in the low (P < .01) and middle (P # .01) tertiles, but there was no difference between low and middle tertiles (P ¼ .48). After adjusting for age, sex, race, and ABI, similar findings were obtained for group differences in HORAC. The concentration of hs-CRP was significantly lower in the high cadence tertile than in the low (P < .01) and middle (P ¼ .01) tertiles, but there was no significant difference in hs-CRP between the low and middle cadence tertiles (P ¼ .26). For the adjusted analyses, similar findings were obtained for group differences in hs-CRP, except that hs-CRP was no longer significantly different between the high and middle cadence tertiles (P ¼ .08). No significant group differences were noted for the endothelial cell biomarkers in either the unadjusted or adjusted analyses.
DISCUSSION
The novel finding in this investigation was that greater amount of daily walking and faster pace of walking HORAC, Hydroxyl radical antioxidant capacity; hs-CRP, high-sensitivity C-reactive protein; NF-kB, nuclear factor kB.
Values are means (standard deviation). a Adjusted for age, sex, race, and ankle-brachial index (ABI).
were positively associated with higher levels of circulating antioxidant capacity in patients who were limited by symptomatic PAD. Second, greater amount and faster pace of daily walking were associated with lower levels of hs-CRP but were not related to endothelial cell biomarkers. Similar findings were obtained after adjusting for age, sex, race, and ABI.
More daily walking is associated with higher circulating antioxidant capacity and lower inflammation. This is the first study to show that circulating antioxidant capacity is higher in symptomatic patients with PAD who take more strides each day than in those in the lowest tertile of daily walking. Walking >2440 strides each day was associated with elevated circulatory HORAC levels in these patients. An acute bout of walking results in ischemia of the lower extremities and increased production of reactive oxygen species and inflammation in patients with PAD. [26] [27] [28] [29] [30] Repeated exposure to these oxidative stress insults leads to an upregulation of the endogenous antioxidant system, suggesting that ischemic preconditioning is a potential explanation for the higher antioxidant capacity in patients who are chronically more active. 31 The finding that higher HORAC levels are associated with greater amounts of daily walking suggests that inflammation should also be lower with increased physical activity. Indeed, the current investigation found that circulating inflammation, measured by hs-CRP, was lower with greater amount of walking. This finding supports our previous study in which hs-CRP was negatively associated with daily walking in patients with PAD and additional studies that found this relationship in patients with coronary heart disease. 12, 32, 33 Faster pace of walking is associated with higher circulating antioxidant capacity and lower inflammation. This is also the first study to show that circulating antioxidant capacity is higher in symptomatic patients with PAD who walk for 30 minutes each day in the fastest cadence tertile compared with those in the lower two cadence tertiles. Specifically, walking at a cadence faster than 31.6 strides/min for 30 minutes each day was associated with elevated circulatory HORAC levels in these patients. Not only do acute bouts of walking lead to ischemia in the lower extremities and high production of reactive oxygen species and inflammation, but it is possible that walking at higher intensity (ie, at a faster pace) may exaggerate the ischemic preconditioning, which may further upregulate the endogenous antioxidant system. 31 This is supported by previous work in which changes in aerobic fitness after 1 year of exercise training were associated with greater resistance to oxidative stress in overweight or obese postmenopausal women. 34 Finally, our current finding that faster cadence of daily walking is associated with lower hs-CRP is supported by our previous study in patients with PAD and by a previous investigation that found vigorous-intensity physical activity to be independently associated with low hs-CRP, whereas light and moderate-intensity physical activity were not associated with hs-CRP. 12, 32 These studies suggest that daily activity performed at relatively faster walking cadences may be more efficacious to increase circulating antioxidant capacity and to lower inflammation than merely walking more each day.
Limitations. There are limitations to this study. A selfselection bias may exist regarding study participation as patients who participated in this trial were volunteers. Therefore, they may represent those who were more interested in participation, who had better access to transportation to the research center, and who had relatively better health than patients who did not volunteer. Furthermore, the results of this study are applicable only to symptomatic patients with PAD and may not be generalized to asymptomatic patients and patients with more severe forms of PAD, such as critical limb ischemia. Another limitation is that we did not have a healthy control group to examine whether similar relationships exist among gait characteristics and inflammation or whether these relationships are unique to patients with PAD. Finally, there are limitations associated with the design of the study. Significant group difference in outcome measures does not provide evidence of causality. Although these limitations exist, we believe that the findings of this study are generalizable to symptomatic patients with PAD because the sample is evenly balanced on race and sex, and typical risk factors and comorbid conditions associated with PAD are highly prevalent.
CONCLUSIONS
Walking >2440 strides each day and walking at a cadence faster than 31.6 strides/min for 30 minutes each day are both associated with greater circulating antioxidant capacity and lower inflammation in symptomatic patients with PAD. The clinical significance is that a home-based walking program may be one approach to increase endogenous antioxidant capacity. 
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